Trade

Dr. Lal PathLabs share price

Balanced risk
  • 25%Low risk
  • 25%Moderate risk
  • 25%Balanced risk
  • 25%High risk
  • 25%Extreme risk
  • ₹2,872.90(-0.51%)
    December 12, 2025 15:48:32 PM IST
    • NSE
    • BSE
  • Vol : 159.75 K (NSE + BSE)
    Last 20 day avg : 132.22 K

Dr. Lal PathLabs is trading -0.51% lower at Rs 2,872.90 as compared to its last closing price. Dr. Lal PathLabs has been trading in the price range of 2,924.00 & 2,853.70. Dr. Lal PathLabs has given -3.84% in this year & -5.53% in the last 5 days. Dr. Lal PathLabs has TTM P/E ratio 48.56 as compared to the sector P/E of 26.98.There are 23 analysts who have initiated coverage on Dr. Lal PathLabs. There are 4 analysts who have given it a strong buy rating & 12 analysts have given it a buy rating. 3 analysts have given the stock a sell rating.The company posted a net profit of 150.60 Crores in its last quarter.Listed peers of Dr. Lal PathLabs include Fortis Healthcare (2.08%), Max Healthcare Institute (-0.63%), Aster DM Healthcare (0.58%).The Mutual Fund holding in Dr. Lal PathLabs was at 15.90% in 30 Sep 2025. The MF holding has increased from the last quarter. The FII holding in Dr. Lal PathLabs was at 21.86% in 30 Sep 2025. The FII holding has increased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Loading...
Key Metrics

Updated on Dec 14, 2025, 08:51 AM UTC

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.96
    Medium volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.07
    Lower than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.87
    Lower than industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    11.07
    Lower than historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    45.00
    Lower than historical values
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    3.75
    Indicates overvaluation
Price range
Day Range
Lowest
2,853.70
Highest
2,924.00
52 week range
Lowest
2,295.10
Highest
3,542.60
Dr. Lal PathLabs News
Dr. Lal PathLabs Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Fortis Healthcare
Moderately Bearish
874.002.0865,983.3478.797.520.1125.92
Max Healthcare Institute
Bearish
1,081.20-0.631,04,886.6493.6411.230.1429.50
Aster DM Healthcare
Moderately Bearish
620.000.5832,123.5095.119.490.7753.36
Apollo Hospitals Enterprise
Bearish
7,102.651.321,02,125.2171.3812.610.2683.18
Narayana Hrudayalaya
Neutral
1,868.05-0.9238,175.6249.2210.850.2359.03
Mutual Fund Ownership
View all
NJ ELSS Tax Saver Scheme Regular Growth
NA
  • Amount Invested (Cr.) 11.42
  • % of AUM 4.22
PGIM India Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 2.64
  • % of AUM 2.42
Nippon India Pharma Fund - Growth
NA
  • Amount Invested (Cr.) 197.61
  • % of AUM 2.37
Quantum Ethical Fund Regular Growth
NA
  • Amount Invested (Cr.) 1.33
  • % of AUM 2.31
DSP Nifty Smallcap250 Quality 50 Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 5.41
  • % of AUM 2.12
Dr. Lal PathLabs Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2025-10-31Qtr Results, Int.Dividend & Bonus issue
2025-07-31Quarterly Results, Dividend & Others
2025-04-25Audited Results & Final Dividend
2025-01-30Quarterly Results, Dividend & Others
2024-10-23Quarterly Results & Interim Dividend
About the company Dr. Lal PathLabs
  • IndustryHealthcare Facilities
  • ISININE600L01024
  • BSE Code539524
  • NSE CodeLALPATHLAB
Dr. Lal PathLabs Limited is an India-based provider of diagnostic and related healthcare tests and services. The Company is engaged primarily in the business of running laboratories for carrying out pathological investigations in various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It offers a range of tests, including Pregnancy Test, Full Body Checkups, Covid 19 Test, Heart Test, Kidney Test, Liver Test, Cholesterol Test, Hepatitis B Test, Kidney Function Test, Sugar Test, Thyroid Test, Typhoid Test, Uric Acid Test, Vitamin B12 Test and vitamin D Test. It has approximately 298 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab in Kolkata, Bangalore and Mumbai), 6,607 patient service centers, and 12,365 pick-up points (PUPs). Its customers include individual patients, hospitals, and corporate customers.
  • Management Info
  • Arvind LalExecutive Chairman of the Board
  • Shankha BanerjeeChief Executive Officer
  • Ved GoelGroup Chief Financial Officer and Chief Executive Officer - International Business
  • Jai MeenaChief Operating Officer
  • Manoj GargGroup Chief Human Resources Officer
  • Munender SopernaGroup Chief Information and Digital Officer
  • Vinay GujralCompliance Officer, Company Secretary
  • Vandana LalWhole-Time Director
Dr. Lal PathLabs Share Price FAQs

Dr. Lal PathLabs is trading at 2872.90 as on Fri Dec 12 2025 10:18:32. This is -0.51% lower as compared to its previous closing price of 2887.55.

The market capitalization of Dr. Lal PathLabs is 24072.45 Cr as on Fri Dec 12 2025 10:18:32.

The average broker rating on Dr. Lal PathLabs is Buy. The breakup of analyst rating is given below -

  • 4 analysts have given a strong buy rating
  • 12 analysts have given a buy rating
  • 1 analysts have given a hold rating
  • 3 analysts have given a sell rating
  • 3 analysts have given a strong sell rating

The 52 wk high for Dr. Lal PathLabs is 3542.60 whereas the 52 wk low is 2295.10

Dr. Lal PathLabs can be analyzed on the following key metrics -

  • TTM P/E: 48.56
  • Sector P/E: 26.98
  • Dividend Yield: 0.87%
  • D/E ratio: 0.07

Dr. Lal PathLabs reported a net profit of 487.14 Cr in 2025.

The Mutual Fund Shareholding was 15.90% at the end of 30 Sep 2025.

Quick Links
EQUITY QUICK LINKS
Dr. Lal PathLabs QUICK LINKS
FROM MARKETS
RELATED LINKS
Quarterly Results
Business News/Market/Market Stats/  Dr. Lal PathLabs share price
✕

Wait for it…

Log in to our website to save your bookmarks. It'll just take a moment.

✕

Wait for it…

Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.